Press Releases

05.01.2024

Pfizer Reports First-Quarter 2024 Results

04.29.2024

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

04.29.2024

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

04.26.2024

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

04.25.2024

Pfizer Announces 2024 Shareholder Meeting Preliminary Results

04.24.2024

Pfizer Declares Second-Quarter 2024 Dividend

04.22.2024

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

04.11.2024

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

04.09.2024

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

03.20.2024

Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts

03.13.2024

European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease

03.12.2024

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)